#4150
Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis
Introduction:
DCC functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Operating as a dependence receptor, DCC induces apoptosis without NTN and promotes cell survival in its presence. In some cancers like small cell lung cancer and neuroblastoma, upregulation of NTN-3 rather than NTN-1 has been observed. However, the precise involvement of NTNs and DCC in PNEN remains unclear.
Conference:
Presenting Author:
Sela Peremen L
Authors:
Sela Peremen L,
Telerman A,
Peshes Yaloz N,
Tirosh A,
Keywords:
neuroendocrine,
netrin,
pancreatic neuroendocrine tumor,
dcc,
#3796
The effect of pseudohypoxia on the immune microenvironment of pancreatic neuroendocrine neoplasms (PanNEN)
Introduction:
Pancreatic neuroendocrine tumors may develop sporadically or as part of an inherited disease, such as von Hippel-Lindau (VHL). VHL disease is caused by a germline pathogenic variant in the VHL gene encoding VHL protein (pVHL). Hypoxia inducible factor (HIF) is responsible for cellular oxygen supply. Its degradation is mediated in normoxic states via ubiquitination and inhibited by pVHL. Hence, pVHL deficiency leads to pseudohypoxia due to HIF overexpression. Several studies suggested immunomodulatory role for HIF in kidney cancer.
Conference:
Presenting Author:
Authors:
Solomon Chmelnik A,
Telerman A,
Tirosh A,
Keywords:
Pancreatic neuroendocrine tumor,
VHL,
DNA methylation,
Immune cells,
PD-L1,
#3688
Novel von Hippel-Lindau-related pancreatic neuroendocrine neoplasms in-vivo model
Introduction:
Von Hippel-Lindau (VHL) disease is a familial cancer syndrome caused by a germline mutation in the VHL tumor suppressor gene. Although VHL-related pancreatic neuroendocrine neoplasms (vPNEN) have been reported, their molecular pathogenesis is not fully investigated.
Conference:
Presenting Author:
Authors:
Telerman A,
Yossef Y,
Chmelnik A,
Tirosh A,
Keywords:
VHL,
PNEN,
BON1,
pseudohypoxia,
CDX,
#3471
A novel in vitro spheroid model enables multi-modality assessment of the anti-tumoral immune response in pancreatic neuroendocrine neoplasms
Introduction:
Patients harbouring pancreatic neuroendocrine neoplasms (PNENs) often present as a non-resectable disease due to distant metastases, hence, efficacy of the current medical intervention is limited. Activation of the mammalian target of rapamycin (mTOR) pathway is a known tumorigenic driver in PNENs. mTOR inhibition by Everolimus (EVE) delays PNEN progression, but the mechanism is not clear. EVE is also used as an immunosuppressant, thus we hypothesized that it may suppress the anti-tumoral immune response.
Conference:
Presenting Author:
Authors:
Nasirov S,
Zaig E,
Mor-Cohen R,
Telerman A,
Tirosh A,
Keywords:
PNEN,
spheroid,
Everolimus,
mTOR,
